TYG Oncology
↗Mansfield, Nottinghamshire, United Kingdom
TYG Oncology is a UK-based biotechnology company specializing in novel cancer immunotherapies utilizing its proprietary S-TIR™ (Specific Total Immune Remodulation) technology platform. The company develops active checkpoint control immunotherapies (ACCI) designed to boost patients' immune systems to generate strong, specific, and controlled immune responses against cancer. TYG Oncology's lead candidate, TYG100, is an anti-gastrin vaccine targeting gastroenterological cancers including pancreatic, gastric, and colorectal cancers. The company is built on the validated gastrin immunotherapy approach previously explored in the predecessor compound G17DT (Gastrimmune) developed by Aphton Corporation, with enhanced immune potency and safety profiles. TYG Oncology combines its proprietary S-TIR platform technology with artificial intelligence and machine learning partnerships to identify novel therapeutic targets and optimize treatment efficacy in oncology.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1 Clinical Trial
Modalities:Therapeutic vaccine, Active checkpoint control immunotherapy, mAb, Cell therapy
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Cancer Research UK / Cancer Research Technology - Phase 1 clinical trial sponsorship and development partnership (2016), OncoQR ML GmbH - Collaboration on therapeutic vaccine development using S-TIR technology platform, Apollomics Inc. - Licensing agreement for Greater China and South Africa (2021, TERMINATED 2025)
COMPETITION
Position:Niche Player
Competitors:BioNTech/Genentech (autogene cevumeran mRNA vaccine for pancreatic cancer), ELI-002 developers (therapeutic vaccine for pancreatic and colorectal cancer), Merck/MSD (pembrolizumab + chemotherapy for gastric cancer), Astellas/Ayala (PT886 targeting claudin 18.2 for gastric/pancreatic cancer), Other checkpoint inhibitor developers targeting GI cancers
LEADERSHIP
Key Executives:
Fred Jacobs - CEO and Founder
Christof Langer - COO and Founder
Geert Mudde - Chief Scientific Officer (CSO)
Paul Broome - Chief Medical Officer (CMO)
Scientific Founders:Dr. Geert Mudde - Inventor of S-TIR™ technology platform
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TYG Oncology. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.